{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:46:50Z","timestamp":1785782810366,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82403210"],"award-info":[{"award-number":["82403210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U22A20326"],"award-info":[{"award-number":["U22A20326"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04228-4","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:06:03Z","timestamp":1763442363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative analysis of immunochemotherapy with versus without radiation therapy for stage IVB esophageal squamous cell carcinoma confined to non-regional nodal metastases: a multicenter propensity score matching study"],"prefix":"10.1007","volume":"74","author":[{"given":"Qi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanji","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conghua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuaile","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"1","key":"4228_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R et al (2024) Cancer incidence and mortality in China, 2022. J Natl Cancer Cent 4(1):47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"4228_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jncc.2023.01.002","volume":"3","author":"R Chen","year":"2023","unstructured":"Chen R, Zheng R, Zhang S, Wang S, Sun K, Zeng H et al (2023) Patterns and trends in esophageal cancer incidence and mortality in China: an analysis based on cancer registry data. J Natl Cancer Cent 3(1):21\u201327. https:\/\/doi.org\/10.1016\/j.jncc.2023.01.002","journal-title":"J Natl Cancer Cent"},{"issue":"12","key":"4228_CR3","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1016\/S2468-2667(21)00157-2","volume":"6","author":"H Zeng","year":"2021","unstructured":"Zeng H, Ran X, An L, Zheng R, Zhang S, Ji JS et al (2021) Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. Lancet Public Health 6(12):e877\u2013e887. https:\/\/doi.org\/10.1016\/S2468-2667(21)00157-2","journal-title":"Lancet Public Health"},{"issue":"5","key":"4228_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.21037\/cco.2017.07.06","volume":"6","author":"GY Ku","year":"2017","unstructured":"Ku GY (2017) Systemic therapy for esophageal cancer: chemotherapy. Chin Clin Oncol 6(5):49. https:\/\/doi.org\/10.21037\/cco.2017.07.06","journal-title":"Chin Clin Oncol"},{"issue":"10302","key":"4228_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T et al (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398(10302):759\u2013771. https:\/\/doi.org\/10.1016\/S0140-6736(21)01234-4","journal-title":"Lancet"},{"issue":"5","key":"4228_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y et al (2023) Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. The Lancet Oncol 24(5):483\u2013495. https:\/\/doi.org\/10.1016\/S1470-2045(23)00108-0","journal-title":"The Lancet Oncol"},{"issue":"10","key":"4228_CR7","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q et al (2021) Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 326(10):916\u2013925. https:\/\/doi.org\/10.1001\/jama.2021.12836","journal-title":"JAMA"},{"issue":"2","key":"4228_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ymthe.2023.12.012","volume":"32","author":"Y Hu","year":"2024","unstructured":"Hu Y, Sun Y, Liao Z, An D, Liu X, Yang X et al (2024) Irradiated engineered tumor cell-derived microparticles remodel the tumor immune microenvironment and enhance antitumor immunity. Mol Ther 32(2):411\u2013425. https:\/\/doi.org\/10.1016\/j.ymthe.2023.12.012","journal-title":"Mol Ther"},{"issue":"5","key":"4228_CR9","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2021.03.047","volume":"110","author":"C Moore","year":"2021","unstructured":"Moore C, Hsu CC, Chen WM, Chen BPC, Han C, Story M et al (2021) Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) in preclinical models enhances single-agent immune checkpoint blockade. Int J Radiat Oncol Biol Phys 110(5):1306\u20131316. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.047","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4228_CR10","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1038\/s41467-019-11906-2","volume":"10","author":"A Arina","year":"2019","unstructured":"Arina A, Beckett M, Fernandez C, Zheng W, Pitroda S, Chmura SJ et al (2019) Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat commun 10(1):3959. https:\/\/doi.org\/10.1038\/s41467-019-11906-2","journal-title":"Nat commun"},{"issue":"5","key":"4228_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"W Theelen","year":"2021","unstructured":"Theelen W, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts J et al (2021) Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 9(5):467\u2013475. https:\/\/doi.org\/10.1016\/S2213-2600(20)30391-X","journal-title":"Lancet Respir Med"},{"issue":"7","key":"4228_CR12","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.jtho.2017.03.026","volume":"12","author":"DM Guttmann","year":"2017","unstructured":"Guttmann DM, Mitra N, Bekelman J, Metz JM, Plastaras J, Feng W et al (2017) Improved overall survival with aggressive primary tumor radiotherapy for patients with metastatic esophageal cancer. J Thorac Oncol 12(7):1131\u20131142. https:\/\/doi.org\/10.1016\/j.jtho.2017.03.026","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4228_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13014-018-1183-y","volume":"13","author":"J Lyu","year":"2018","unstructured":"Lyu J, Li T, Wang Q, Li F, Diao P, Liu L et al (2018) Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study. Radiat Oncol 13(1):233. https:\/\/doi.org\/10.1186\/s13014-018-1183-y","journal-title":"Radiat Oncol"},{"issue":"1","key":"4228_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijrobp.2019.12.033","volume":"108","author":"SI Gutiontov","year":"2020","unstructured":"Gutiontov SI, Pitroda SP, Chmura SJ, Arina A, Weichselbaum RR (2020) Cytoreduction and the optimization of immune checkpoint inhibition with radiation therapy. Int J Radiat Oncol Biol Phys 108(1):17\u201326. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.12.033","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"4228_CR15","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","volume":"23","author":"SJ Dovedi","year":"2017","unstructured":"Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R et al (2017) Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin Cancer Res 23(18):5514\u20135526. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1673","journal-title":"Clin Cancer Res"},{"key":"4228_CR16","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ et al (2017) DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 8:15618. https:\/\/doi.org\/10.1038\/ncomms15618","journal-title":"Nat Commun"},{"issue":"12","key":"4228_CR17","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C et al (2018) Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 24(12):1845\u20131851. https:\/\/doi.org\/10.1038\/s41591-018-0232-2","journal-title":"Nat Med"},{"issue":"11","key":"4228_CR18","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1080\/09553002.2021.1969051","volume":"97","author":"D Li","year":"2021","unstructured":"Li D, Guan Y, Dong Y, Wu J, Zhang Y, Chen R et al (2021) Radiochemotherapy upregulates expression of checkpoint receptors on circulating T cells. Int J Radiat Biol 97(11):1563\u20131568. https:\/\/doi.org\/10.1080\/09553002.2021.1969051","journal-title":"Int J Radiat Biol"},{"issue":"5","key":"4228_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1667\/RADE-22-00061.1","volume":"198","author":"S Hao","year":"2022","unstructured":"Hao S, Zhang X, Han L, Ma X, Nie Y, Deng J et al (2022) PD-1 Inhibitor enhanced radiosensitivity by reactivating T cells and inducing G2\/M phase arrest in esophageal squamous cell carcinoma. Radiat Res 198(5):458\u2013466. https:\/\/doi.org\/10.1667\/RADE-22-00061.1","journal-title":"Radiat Res"},{"key":"4228_CR20","doi-asserted-by":"publisher","first-page":"109679","DOI":"10.1016\/j.radonc.2023.109679","volume":"184","author":"W Zhao","year":"2023","unstructured":"Zhao W, Ke S, Cai X, Zuo Z, Shi W, Qiu H et al (2023) Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: an open-label, single-arm, phase II trial. Radiother Oncol 184:109679. https:\/\/doi.org\/10.1016\/j.radonc.2023.109679","journal-title":"Radiother Oncol"},{"issue":"1","key":"4228_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12893-017-0247-5","volume":"17","author":"F Cavallin","year":"2017","unstructured":"Cavallin F, Alfieri R, Scarpa M, Cagol M, Ruol A, Fassan M et al (2017) Nodal skip metastasis in thoracic esophageal squamous cell carcinoma: a cohort study. BMC Surg 17(1):49. https:\/\/doi.org\/10.1186\/s12893-017-0247-5","journal-title":"BMC Surg"},{"issue":"39","key":"4228_CR22","doi-asserted-by":"publisher","first-page":"65171","DOI":"10.18632\/oncotarget.18015","volume":"8","author":"X Li","year":"2017","unstructured":"Li X, Zhao L, Zhang W, Yang C, Lian Z, Wang S et al (2017) Prognostic value of supraclavicular nodes and upper abdominal nodes metastasis after definitive chemoradiotherapy for patients with thoracic esophageal squamous cell carcinoma. Oncotarget 8(39):65171\u201365185. https:\/\/doi.org\/10.18632\/oncotarget.18015","journal-title":"Oncotarget"},{"issue":"4","key":"4228_CR23","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.ijrobp.2024.06.008","volume":"120","author":"B Chen","year":"2024","unstructured":"Chen B, Chen W, Cheng Q, Zhang H, Wang B, Xu Y et al (2024) Comparison of efficacy and safety of combined chemoimmunotherapy with or without radiation therapy for stage IVB esophageal squamous cell carcinoma: a multicenter propensity score matching analysis. Int J Radiat Oncol Biol Phys 120(4):1084\u20131095. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.06.008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4228_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/doy074","author":"R Zhang","year":"2019","unstructured":"Zhang R, Jia M, Li P, Han J, Huang K, Li Q et al (2019) Radiotherapy improves the survival of patients with metastatic esophageal squamous cell carcinoma: a propensity score matched analysis of Surveillance, Epidemiology, and End Results database. Dis Esophagus\u202f: Official J Int Soc Dis Esophagus \/ ISDE. https:\/\/doi.org\/10.1093\/dote\/doy074","journal-title":"Dis Esophagus : Official J Int Soc Dis Esophagus \/ ISDE."},{"key":"4228_CR25","doi-asserted-by":"publisher","first-page":"217411","DOI":"10.1016\/j.canlet.2024.217411","volume":"611","author":"J Li","year":"2024","unstructured":"Li J, Wang X, Cao J, Fan C, Xiao Q, Zheng Z et al (2024) Immunochemotherapy plus radiotherapy versus immunochemotherapy alone as first-line treatment for treatment-naive, advanced esophageal squamous cell carcinoma (AEC-ICR-1st): a multi-center cohort study. Cancer Lett 611:217411. https:\/\/doi.org\/10.1016\/j.canlet.2024.217411","journal-title":"Cancer Lett"},{"key":"4228_CR26","doi-asserted-by":"publisher","first-page":"887525","DOI":"10.3389\/fonc.2022.887525","volume":"12","author":"J Wu","year":"2022","unstructured":"Wu J, Deng R, Ni T, Zhong Q, Tang F, Li Y et al (2022) Efficacy and safety of radiotherapy\/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: a systematic review and meta-analysis. Front Oncol 12:887525. https:\/\/doi.org\/10.3389\/fonc.2022.887525","journal-title":"Front Oncol"},{"issue":"1","key":"4228_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/vaccines13010069","volume":"13","author":"S Balkhi","year":"2025","unstructured":"Balkhi S, Bilato G, De Lerma BA, Orecchia P, Poggi A, Mortara L (2025) Efficacy of anti-cancer immune responses elicited using tumor-targeted IL-2 cytokine and its derivatives in combined preclinical therapies. Vaccines 13(1):69. https:\/\/doi.org\/10.3390\/vaccines13010069","journal-title":"Vaccines"},{"issue":"1","key":"4228_CR28","doi-asserted-by":"publisher","first-page":"7116","DOI":"10.1038\/s41467-024-51105-2","volume":"15","author":"L Wu","year":"2024","unstructured":"Wu L, Li B, Wan G, Wang Y, Zhu J, Liang L et al (2024) Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trial. Nat Commun 15(1):7116. https:\/\/doi.org\/10.1038\/s41467-024-51105-2","journal-title":"Nat Commun"},{"key":"4228_CR29","doi-asserted-by":"crossref","unstructured":"Bradley JD (2024) Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2. ELCC, abstr LBA1","DOI":"10.1016\/j.esmoop.2024.102986"},{"key":"4228_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.08.013","author":"K Higgins","year":"2024","unstructured":"Higgins K, Hu C, Ross HJ, Jabbour SK, Kozono DE, Owonikoko TK et al (2024) Concurrent chemoradiation \u00b1 atezolizumab (atezo) in limited-stage small cell lung cancer (LS-SCLC): results of NRG oncology\/alliance LU005. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.08.013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4228_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2468-1253(23)00316-3","volume":"9","author":"Q Liu","year":"2024","unstructured":"Liu Q, Chen J, Lin Y, Ye J, Shen W, Luo H et al (2024) Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 9(1):45\u201355. https:\/\/doi.org\/10.1016\/S2468-1253(23)00316-3","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"4228_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.21037\/atm-22-2779","volume":"10","author":"P Zhang","year":"2022","unstructured":"Zhang P, Hou X, Cai B, Yu W, Chen J, Huang X et al (2022) Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world. Ann Transl Med 10(12):708. https:\/\/doi.org\/10.21037\/atm-22-2779","journal-title":"Ann Transl Med"},{"issue":"3","key":"4228_CR33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","volume":"40","author":"ZX Wang","year":"2022","unstructured":"Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J et al (2022) Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell 40(3):277\u2013288. https:\/\/doi.org\/10.1016\/j.ccell.2022.02.007","journal-title":"Cancer Cell"},{"issue":"7","key":"4228_CR34","doi-asserted-by":"publisher","first-page":"e1110","DOI":"10.1002\/onco.13797","volume":"26","author":"W Zhang","year":"2021","unstructured":"Zhang W, Yan C, Gao X, Li X, Cao F, Zhao G et al (2021) Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma. Oncologist 26(7):e1110\u2013e1124. https:\/\/doi.org\/10.1002\/onco.13797","journal-title":"Oncologist"},{"key":"4228_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-024-02199-6","author":"X Lv","year":"2024","unstructured":"Lv X, Wu Y, Li Q, Zheng C, Lin Q, Pang Q et al (2024) Treatment-related pneumonitis after thoracic radiotherapy\/chemoradiotherapy combined with anti-PD-1 monoclonal antibodies in advanced esophageal squamous cell carcinoma. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-024-02199-6","journal-title":"Strahlenther Onkol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04228-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04228-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04228-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:45:19Z","timestamp":1764600319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04228-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4228"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04228-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The study protocol received approval from ethics review boards at Fudan University Shanghai cancer center (No.2109243\u201313). This study was registered at the Clinicaltrials.gov registry (identification number NCT 05142709). The requirement for written informed consent was waived because this study retrospectively analyzed anonymized patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"375"}}